2 results
Approved WMORecruiting
Primary objectivesPart 1 Dose Escalation (with or without LDSC-IL2)• To investigate the safety and tolerability of LAVA-1207 in patients with therapy refractory mCRPC.• To determine the RP2D of LAVA-1207 in patients with therapy refractory mCRPC.…
Approved WMOPending
The primary objectives of this trial are:• Part 1 (dose escalation): To evaluate the safety of BYON4228 alone and in combinationwith rituximab to determine the maximum tolerated dose (MTD), or optimal biological dose(OBD) if the MTD is not reached,…